← 返回

食管鳞状细胞癌微环境中 PD-1/PD-L1 轴的多维调控网络:对新型联合治疗和精准免疫治疗的意义(综述)

英文原题:The multidimensional regulatory network of the PD‑1/PD‑L1 axis in the esophageal squamous cell carcinoma microenvironment: Implications for novel combination therapies and precision immunotherapy (Review).

查看英文原题

The multidimensional regulatory network of the PD‑1/PD‑L1 axis in the esophageal squamous cell carcinoma microenvironment: Implications for novel combination therapies and precision immunotherapy (Review).

PubMed 2025/11/14(内容时间) Oncol Rep Q2 · IF 4.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

食管癌是全球范围内高度流行的恶性肿瘤。尽管免疫治疗,尤其是程序性细胞死亡‑1/程序性细胞死亡配体1(PD‑1/PD‑L1)抑制剂,已显著改善患者预后,但总体缓解率仍然有限。这种有限的疗效在很大程度上归因于肿瘤微环境(TME)内复杂的免疫抑制网络。本综述系统剖析了食管鳞状细胞癌(ESCC)TME中PD‑1/PD‑L1信号轴的多方面调控机制及其对免疫治疗疗效的影响。新出现的证据表明,TME内的多种免疫抑制机制塑造了对免疫检查点抑制剂的反应:调节性T细胞通过TGF‑β‑PD‑1/PD‑L1轴增强免疫抑制;IL‑6/STAT3信号通路上调PD‑L1表达,而线粒体重塑和氨基酸网络调控加剧T细胞耗竭。

同时,三级淋巴结构(TLS)成熟通过促进组织驻留记忆T细胞活化并增强抗肿瘤免疫,与临床预后呈正相关。相比之下,肿瘤突变负荷(TMB)的预测价值受到TME异质性的限制。新兴策略凸显了TLS成熟度和TMB的预测潜力,尽管TMB在ESCC中的预测相关性仍不一致。联合治疗策略在逆转T/NK 细胞耗竭和重塑免疫抑制性TME方面显示出前景。未来研究应将多组学数据与临床信息相结合,以开发针对ESCC的个体化免疫治疗模型。

展开英文摘要原文

Esophageal cancer is a highly prevalent malignancy worldwide. Although immunotherapy, particularly programmed cell death‑1/programmed cell death ligand 1 (PD‑1/PD‑L1) inhibitors, has notably improved patient outcomes, the overall response rate remains limited. This limited efficacy is largely attributed to complex immunosuppressive networks within the tumor microenvironment (TME). The present review systematically dissects the multifaceted regulatory mechanisms of the PD‑1/PD‑L1 signaling axis in the TME of esophageal squamous cell carcinoma (ESCC), and its impact on immunotherapeutic efficacy. Emerging evidence indicates that multiple immunosuppressive mechanisms within the TME shape the response to immune checkpoint inhibitors: Regulatory T cells enhance immunosuppression via the TGF‑β‑PD‑1/PD‑L1 axis; IL‑6/STAT3 signaling upregulates PD‑L1 expression and mitochondrial remodeling and amino acid network regulation exacerbate T cell exhaustion.

Meanwhile, tertiary lymphoid structure (TLS) maturation is positively associated with clinical prognosis by promoting tissue‑resident memory T cell activation and enhancing antitumor immunity. By contrast, the predictive value of tumor mutational burden (TMB) is constrained by TME heterogeneity.

Emerging strategies highlight the predictive potential of TLS maturity and TMB, although the predictive relevance of TMB in ESCC remains inconsistent. Combination approaches show promise in reversing T/natural killer cell exhaustion and remodeling immunosuppressive TMEs. Future research should combine multi‑omics data with clinical information to develop personalized immunotherapy models for ESCC.

论文信息

作者
Lai H、Qi L、Lin Z、Li Z
单位
Department of Head and Neck Oncology, Second Clinical College, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China.China
文献类型
综述
期刊
Oncology reports2026 Jan
原文标识
PubMed 41235683 · DOI 10.3892/or.2025.9021